Mitigating MACE Risk in T2D & ASCVD

Be part of the knowledge.™

Mitigating MACE Risk in T2D & ASCVD

Mitigating MACE Risk in T2D & ASCVD

What strategies and guidelines can we use to reduce the risk of cardiovascular events in patients with both type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD)? Join leading experts in this four-part series to find out.

Novo Nordisk is a registered trademark of Novo Nordisk A/S.
© 2022 Novo Nordisk All rights reserved.
US22DI00407 December 2022

26

LikeLikedUnlike

Episodes 1-4 of 4

- Jennifer Caudle, DO
  Peer
- Robert J. Chilton, DO
  Peer
3
Heart Matters
Cardiovascular Risk Reduction in Type 2 Diabetes & ASCVD: An Interventional Cardiologist’s Perspective
Cardiovascular Risk Reduction in Type 2 Diabetes & ASCVD: An Interventional Cardiologist’s Perspective
- Matthew Jay Budoff, MD
  Peer
7
Heart Matters
Type 2 Diabetes & ASCVD: Cardiovascular Risk Reduction According to the Guidelines
Type 2 Diabetes & ASCVD: Cardiovascular Risk Reduction According to the Guidelines
- Charles Turck, PharmD, BCPS, BCCCP
  Peer
- Matthew Jay Budoff, MD
  Peer
- Joshua Stolker, MD
  Peer
10
Heart Matters
Cardiovascular Risk Reduction for Adults With Type 2 Diabetes & ASCVD: A Collaborative Approach
Cardiovascular Risk Reduction for Adults With Type 2 Diabetes & ASCVD: A Collaborative Approach
- Jennifer Caudle, DO
  Peer
- Joshua Stolker, MD
  Peer
6
Heart Matters
Treating the Individual: Personalized Care Strategies for Patients With Type 2 Diabetes & ASCVD
Treating the Individual: Personalized Care Strategies for Patients With Type 2 Diabetes & ASCVD

Program Chapters

Segment Chapters

Playlist:

Recommended